OncRef

Clinical Trial: NCT04947319

Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:Ono Pharmaceutical Co., Ltd.
Information Provided By:Ono Pharmaceutical Co., Ltd.
Last Update Posted:2026-03-30

Study Overview

Brief Summary

This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)

Official Title

An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)

Conditions

Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma

Intervention / Treatment

  • Drug: Tirabrutinib
  • Drug: Tirabrutinib
  • Drug: Tirabrutinib

Other Study ID Numbers

  • ONO-4059-09

Start Date (Actual)

2021-12-29

Primary Completion Date (Actual)

2026-01-27

Study Completion Date (Estimated)

2027-03-31

Enrollment (Actual)

119

Study Type

Interventional

Phase

Phase 2